MIPHARM SPA

Pharma Tech

Corning Incorporated | November 19, 2021

Corning Incorporated introduced Corning Velocity® Vials, specially engineered Type I borosilicate vials externally coated with the company’s proprietary technology, which are helping industry-leading drugmakers respond to the pandemic at speed. The increased efficiency and throughput enabled by Velocity Vials can drive faster manufacturing of COVID-19 vaccines, helping address industry supply chain challenges and meet global demand. Velocity Vials can deliver better econ...

Prnewswire | August 17, 2020

Lannett Company, Inc. today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of Flovent® Diskus® (Fluticasone Propionate Powder Inhaler) of Respirent Pharmaceuticals Co. Ltd. According to the Orange Book, all patents covering Flovent Diskus have expired. U.S. sales of Flovent Diskus, which have been increasing in recent years, were $94 million for the 12 months ending June, 2020 according to IQVIA, although actual gene...

Pharma Tech

ArisGlobal | December 08, 2021

ArisGlobal, the leading provider of life sciences software that automates core drug development with its end-to-end drug development technology platform LifeSphere® announced its partnership with Overland Pharmaceuticals. Overland, a premier biopharmaceutical company bringing innovative medicines to underserved patients in Asia and worldwide, selected ArisGlobal's LifeSphere Multivigilance program to centralize pharmacovigilance activities and further develop and commercialize advances i...

Research

Ascentage Pharma | November 30, 2020

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, ongoing hepatitis B (CHB), and age-related infections, today reported it has gone into a concurrence with the University of Michigan, through which the organization may acquire the selective worldwide rights to a MDM2 protein degrader created utilizing the Proteolysis-Targeting Chimeras (PROTACs) innovation. The medication competitor is ...